Sign In
News Digest /
Lukas Schmidt
Author: Lukas Schmidt
05:13am, Tuesday, Jul 30, 2024
Shares of ASML Holding NV surged after Barclays upgraded its rating to 'Overweight' and raised the price target from €930 to €1150, signaling a potential 40% upside. Analysts see a buying opportunity despite recent challenges, forecasting robust long-term growth.
05:37am, Monday, Jul 29, 2024
Billionaire investors like Gates, Buffett, and Dalio remain committed to snack and fast-food stocks, citing resilience during downturns and emerging market potential. Despite worries over weight-loss drugs, analysts believe demand for convenience will sustain these iconic brands.
05:30am, Monday, Jul 29, 2024
Alibaba's shares surged 5.8% in Hong Kong after announcing new service fees for merchants on Tmall and Taobao, aimed at boosting revenue. Analysts view the change positively, though smaller merchants may see fee waivers to maintain engagement. The move aligns Alibaba with industry trends, signali...
05:06am, Monday, Jul 29, 2024
Nissan (OTC: NSANY) plans to cut production by nearly one-third at its Kyushu plant amid declining U.S. demand for older models, notably the Rogue. With 640,000 unsold vehicles, the brand faces significant challenges against competitors like Toyota and Honda.
05:00am, Monday, Jul 29, 2024
Heineken N.V. (AMS: HEIO) shares fell sharply after disappointing Q2 results, missing expectations on key metrics. Despite this, the company has raised its FY 2024 profit growth outlook to 4-8%. Analysts remain cautious, with RBC rating the stock as “Underperform.”
04:55am, Monday, Jul 29, 2024
Philips (PHG) reported a strong Q2, with EBITA hitting €495M, exceeding forecasts. Shares rose 7% as cost-cutting and insurance revenue bolstered profits. The company remains optimistic about overcoming recent challenges in the medical device market.
04:43am, Monday, Jul 29, 2024
Ark Investment's Cathie Wood calls Tesla (NASDAQ: TSLA) a prime AI opportunity, predicting its stock could hit $2,600 by 2029. However, with declining growth, rising competition, and a high P/E ratio, investors may want to wait for a more stable outlook.
03:39am, Friday, Jul 26, 2024
CrowdStrike (NASDAQ: CRWD) faces backlash after a recent faulty system update disrupted operations across major sectors, echoing a similar past incident during CEO George Kurtz’s stint at McAfee. The stock plummeted nearly 21% as trust wavers.
03:37am, Friday, Jul 26, 2024
Eli Lilly & Co. (NYSE: LLY) faces a $120 billion market cap loss as rivals advance in the obesity drug space. With a stock drop of 14% in eight days, analysts warn of looming challenges despite a positive year-to-date. The upcoming earnings report could be pivotal.
03:30am, Friday, Jul 26, 2024
In the AI stock arena, SoundHound AI (SOUN) outshines C3.ai (AI) with a 128% surge this year, despite high valuations. C3.ai struggles with losses, yet has a lower P/S ratio. Investors should weigh growth potential against profitability concerns before investing.
03:26am, Friday, Jul 26, 2024
Man Group (LSE: EMG) reports a 17.5% increase in assets under management, reaching $178.2 billion, driven by strong liquid credit strategies. Despite a 65% drop in net inflows for 2024, CEO Robyn Grew remains optimistic about future market adaptability.
08:17am, Wednesday, Jul 24, 2024
NVIDIA (NASDAQ: NVDA) shares dipped 1.6% after Elon Musk announced Tesla's plans to enhance its Dojo supercomputer project, raising concerns about GPU supply and pricing. Traders should monitor NVIDIA's market position amid Tesla's increasing competition.
08:02am, Wednesday, Jul 24, 2024
NextEra Energy (NYSE: NEE) reported Q2 earnings with an EPS of $0.96, beating estimates by $0.03, but revenue fell to $6.07 billion, below the $7.15 billion consensus. The stock is up 9.27% over three months, but down 4.41% year-over-year. Traders should watch for EPS guidance of $3.23-$3.43 for ...
07:53am, Wednesday, Jul 24, 2024
Thermo Fisher Scientific (NYSE: TMO) raises its annual profit guidance due to increased demand for biomedical tools, reporting strong second-quarter earnings. Despite a slight stock dip, positive signs in biotech funding suggest a promising outlook for investors.
